- Jul 19, 2009
- 1,065
- 1
- 10,480
Yes. Add that as possibility #4: The most dominant riders over the past 20 yrs were the biggest "responders" to EPO. What this implies is that the performance enhancement must be greater, not by just enough to offset the natural advantage than some other rider possesses who is physiologically more gifted, but it must exceed that by a significant margin in order for dominance to be achieved over that rider. Remember, we aren't just talking about riders who beat their peers occasionally.Race Radio said:You forgot the most obvious. There is a great variance in how an individual rider reacts to pharmacology. This is true with any medical intervention. Some see significant benefit, others little, others none
On this point, I looked up a number of studies and the average increase in VO2max in response to EPO is about 10% and the SD is about 5%. Oxygen consumption is linearly related to peak power output (on a VO2max test) and thus we might expect to see around a 10-15% increase in PPO resulting form EPO use (as shown in the figure posted a few pages back). However, if you look at the SD of PPO for professional cyclists you'll find that it is also about 10%.
So if an average rider has a PPO of about 450W. That would mean that a GT contender at the top of the crop would possibly have a PPO closer to 490-500W.
So if the tour contender got an average 10% increase in PPO from EPO that would bring it up to about 540-550W. That would mean the average rider will require an increase of about 100W which is 22%, just be equal. You would need at least another 3 or 4% to be better and probably 5-7% to dominate. So we are looking at a 25-30% increase in PPO. Since the mean increase is about 10% and the SD is about 5%, that means the average rider would need a performance enhancement that is at least 3 SDs ABOVE the mean response. 3 SDs is equivalent to a probability of 0.1%.
Of course, the limitation of this little analysis is that it is restricted to EPO. The only people that really know what sort of performance changes can be achieved with a PED cocktail are the riders and team doctors themselves. However, I was responding to a post which stated that EPO can change an average rider into a tour winner, and it has been shown that the main effect of EPO on performance enhancement is due to the increase in VO2max.
Now all this aside, something that I have always found very conspicuously MISSING from the clinic discussions is the effect of non-doping factors on performance such as genetics, training, emotional stress, nutrition, illness, injury, sleep. It seems like too many people want to attribute variations in performance between riders and seasons mainly to variations in doping program effectiveness rather than overall preparation.
To me it just makes more sense to attribute the dominance of Indurain, Armstrong, Ullrich and Contador (in particular) to a combination of factors rather than simply "doping program" and "response to doping". This idea that any average rider can come along and become a tour winner simply due to EPO mainly relies on the assumption that none of the real contenders are doping, but we know this is pretty much baloney. It is much more complicated than that.